Price
No data yet.
Social Signal Score
Analyst Ratings
37 analystsRevenue
$307.96M+5745.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Catherine E. Owen Adams
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 797
- Beta
- 0.86
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.71
Financials
Revenue
$307.96M+5745.8%Net Income
$31.50MEBITDA
$32.36MFree Cash Flow
$124.46MEPS (diluted)
$0.18Shares Outstanding (diluted)
172.85M+47.1%Operating Expenses
$241.81MCash & Debt
$956.47MRevenue by Segment (annual)
$223.81MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.07B | $391.00M | $2.32 |
| 2024 | $957.80M | $226.45M | $1.37 |
| 2023 | $726.44M | $-61.29M | $-0.37 |
| 2022 | $517.24M | $-215.97M | $-1.34 |
| 2021 | $484.14M | $-167.87M | $-1.05 |
| 2020 | $441.75M | $-281.58M | $-1.79 |
| 2019 | $339.08M | $-235.26M | $-1.60 |
| 2018 | $223.81M | $-245.19M | $-1.94 |
| 2017 | $124.90M | $-289.40M | $-2.36 |
| 2016 | $17.33M | $-271.39M | $-2.34 |
| 2015 | $61.0K | $-164.44M | $-1.63 |
| 2014 | $120.0K | $-92.47M | $-0.95 |
| 2013 | $1.15M | $-37.95M | $-0.44 |
| 2012 | $4.91M | $-20.85M | $-0.38 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.39
- Implied price
- $40.71
- Return from $19.95
- 15.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $20.24 — today's price is already 1.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 8 | 10 | 12 | 14 | 16 |
|---|---|---|---|---|---|
| -2.0% | -3.5% | 0.9% | 4.7% | 7.9% | 10.9% |
| 3.0% | 1.4% | 6.1% | 10.0% | 13.4% | 16.5% |
| 8.0% | 6.4% | 11.2% | 15.3% | 18.9% | 22.2% |
| 13.0% | 11.3% | 16.4% | 20.7% | 24.5% | 27.8% |
| 18.0% | 16.2% | 21.5% | 26.0% | 30.0% | 33.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
75+0.96%Social Signal Score
Mentions (20)
- Newszacks.com·6d ago·Positive
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
View source ↗ - Newszacks.com·10d ago·Negative
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
View source ↗ - Newsseekingalpha.com·11d ago·Positive
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
View source ↗ - News (RSS)investing·11d ago·Neutral
Why is ACADIA Pharmaceuticals stock tumbling today?
View source ↗ - Newsbenzinga.com·11d ago·Negative
Acadia Drug Misses Primary Goal in Alzheimer's Related Psychosis Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) stock is trading lower on Thursday after the company announced topline Phase 2 results from its RADIANT clinical trial program evaluating remlifanserin for Alzheimer's disease psychosis.
View source ↗ - News (Marketaux)gurufocus.com·11d ago·Positive
ACAD Looks 0.8% Undervalued on GF Value™ as Clinical Trial Progresses On September 24, 2026, ACADIA <[+327 characters]
View source ↗ - Newsseekingalpha.com·11d ago·Negative
Acadia Pharmaceuticals: Remlifanserin Is In Trouble Acadia Pharmaceuticals (ACAD) reported phase 2/3 results for remlifanserin in Alzheimer's disease psychosis, with the high dose missing statistical significance but showing positive efficacy trends. Remlifanserin's safety profile was clean, but the effect size on the primary endpoint was low, raising concerns about clinical utility and replicability in phase 3. I am now even less optimistic about remlifanserin's phase 3 success, lowering my pro…
View source ↗ - Newsproactiveinvestors.com·11d ago·Negative
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis. The once-daily 60 mg dose eased hallucinations and delusions more than placebo on the trial's main measure, but the result fell just short of statistical significance at six weeks.
View source ↗ - Newsmarketbeat.com·11d ago·Negative
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer's Psychosis Trial ACADIA Pharmaceuticals NASDAQ: ACAD reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer's disease psychosis, or ADP. The company said the 60 mg once-daily dose narrowly missed statistical significance on the primary endpoint but showed nominal statistical significance on a key secondary endpoint, whi…
View source ↗ - Newsreuters.com·12d ago·Negative
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study Acadia Pharmaceuticals said on Thursday its experimental drug for psychosis associated with Alzheimer's missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions in patients with the condition.
View source ↗ - News (RSS)financialpost·26d ago·Negative
ARC Secures $60 Million Growth Investment from Acadia to Transform Frontline Asset Management Technology Investment will accelerate commercial expansion and innovation of ARC’s platform that has helped customers reduce device shrink by 95%, increase device utilization by more than 20%, and unlock significant operational savings PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) — ARC by ChargeItSpot, an enterprise device management platform helping industry-leading retailers and supply chain organiza
View source ↗ - News (RSS)seekingalpha·29d ago·Neutral
Acadia Realty Trust: An Excellent Retail REIT, With More To Come
View source ↗ - News (RSS)seekingalpha·42d ago·Neutral
Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple
View source ↗ - News (Marketaux)seekingalpha.com·42d ago·Neutral
Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple (NASDAQ:ACAD) Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple (NASDAQ:ACAD)
View source ↗ - Newszacks.com·42d ago·Negative
Acadia Gets European Commission Nod for Daybu in Rett Syndrome ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
View source ↗ - Newsgurufocus.com·43d ago·Negative
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the
View source ↗ - Newsbusinesswire.com·43d ago·Negative
… as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “…
View source ↗ - News (RSS)seekingalpha·43d ago·Neutral
Acadia Healthcare Company Isn't Great, But The Big Picture Justifies Optimism
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.
View source ↗ - News (RSS)fool·55d ago·Positive
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.21 per share
Typical surprise +164.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.18 vs $0.07beat
- Wed, May 6$0.02 vs $0.04miss
- Wed, Feb 25$1.60 vs $0.14beat
- Wed, Nov 5$0.42 vs $0.14beat
- Wed, Aug 6$0.16 vs $0.14beat
- Wed, May 7$0.11 vs $0.10beat
Estimates and results for ACAD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACAD officers and directors.
- Bought
- —
- Sold
- $2.6m
0 trades
22 trades
- Schneyer Mark C.sold
- Schneyer Mark C.sold
- Schneyer Mark C.sold
- Thompson Elizabeth H.z.sold
- Thompson Elizabeth H.z.sold
- Kihara Jamessold
- Kihara Jamessold
- Kihara Jamessold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Nov 6, 2020 (59d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Mar 8, 2019 (17d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.